ReShape Lifesciences Inc. (RSLS)
|Net Income (ttm)||-21.63M|
|Trading Day||May 7|
|Day's Range||4.15 - 4.52|
|52-Week Range||1.51 - 11.50|
SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter an...
Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, Marc...
Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T SAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally inv...
ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomac... [Read more...]
|IPO Date |
Nov 15, 2007
|Stock Exchange |
|Ticker Symbol |
In 2020, RSLS's revenue was $11.30 million, a decrease of -25.12% compared to the previous year's $15.09 million. Losses were -$21.63 million, -70.85% less than in 2019.